Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up News

Executive Summary

Noteworthy news from medtech start-ups. This month we profile Cardiophotonics, whose HeartLight monitor measures patient fluid volumes in real time and NeoTract, which is developing a minimally invasive device for treating benign prostatic hyperplasia.

You may also be interested in...



CTIS: EU Industry Welcomes ‘Landmark Moment’ But Says Issues Still Need Addressing

EFPIA acknowledges that while the mandatory use of the EU Clinical Trials Information System from today is a significant milestone, it says the usability and functionality of the system need to be enhanced and there are also issues with the Clinical Trials Regulation that need to be fixed.

‘Quick Guide’ To Help EU Clinical Trial Sponsors As CTIS Hits 31 January Milestone

Just a day before it became mandatory to use the single-portal Clinical Trial Information System, the European Commission published concise advice for sponsors and investigators who want to conduct trials in Europe.

Pfizer’s COVID-19 Franchise Dominates Best-Seller List

Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel